Lancet oncol: Enfortumab vedotin can be used for locally advanced or metastatic urothelial cancer that is not suitable for platinum after anti-PD-1 treatment!

Locally advanced or metastatic urothelial cancer is usually incurable, and there are few treatment options, especially for patients who have previously received anti-PD-1 or PD-L1 therapy and do not meet the requirements of cisplatin therapy.

Enfortumab vedotin is an antibody-drug conjugate (ADC) formed by coupling the human IgG1 monoclonal antibody enfortumab targeting Nectin-4 (a protein highly expressed in urothelial cancer) and the cytotoxic agent MMAE .

Enfortumab vedotin is an antibody-drug conjugate (ADC) composed of human IgG1 monoclonal antibody enfortumab targeting Nectin-4 (a protein highly expressed in urothelial cancer) conjugated with the cytotoxic agent MMAE

This study aims to evaluate the efficacy and safety of Enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer who are not suitable for platinum after immunotherapy .

immunity

EV-201 is a multi-center, single-arm phase 2 clinical application that recruits patients with locally advanced or metastatic urothelial cancer who have previously received PD-1 or PD-L1 inhibitor treatment.

A: Volume change of the target lesion; B: Objective remission

A: Volume change of the target lesion; B: Objective remission

From October 8, 2017 to February 11, 2020, a total of 91 patients were recruited, of which 89 received Enfortumab vedotin treatment.

The median follow-up was 13.

A: progression-free survival; B: overall survival

A: progression-free survival; B: overall survival

Of the 89 patients, 49 (55%) had treatment-related adverse events of grade 3 and above.

Fifteen patients had serious treatment-related adverse reactions.

Three patients died of acute kidney injury, metabolic acidosis, and multiple organ dysfunction syndrome respectively within 30 days after the first medication.

In previously treated PD-1 or PD-L1 treatment inhibitor patients with locally advanced or metastatic urothelial carcinoma, tolerance Enfortumab vedotin good response rate can reach 52% in previously treated PD-1 or PD -In patients with locally advanced or metastatic urothelial cancer treated with L1 inhibitors, Enfortumab vedotin is well tolerated, and the remission rate can reach 52%

Original source:

Original source:

Evan Y Yu, et al.

Leave a message here